Adenomyosis vs Endometriosis: How Two Uterine Diseases Differ and Overlap

Adenomyosis and endometriosis are distinct diseases with one shared engine: endometrial-like tissue growing where it does not belong and bleeding in response to hormones. In adenomyosis, that tissue invades the muscular wall of the uterus itself; in endometriosis, it implants outside the uterus, most often on the pelvic peritoneum and ovaries. Both cause pelvic pain and heavy bleeding, but their mechanisms, imaging findings, and first-line treatments differ. Roughly 20 percent of women with adenomyosis also have endometriosis, so the two frequently coexist rather than exclude each other.

The shared mechanism: tissue that bleeds where it should not

Both conditions begin with tissue that behaves like the uterine lining. That tissue contains glands and stroma, and it responds to estrogen and progesterone exactly as the endometrium does. Each month it thickens, then breaks down and bleeds. The problem is location: when that bleeding occurs inside a muscle wall or a closed peritoneal space, the body cannot shed it through the cervix.

In endometriosis, this repeated micro-bleeding provokes inflammation, scar tissue, and adhesions. The lesions release prostaglandins, cytokines, and nerve-sensitizing factors that sensitize pelvic nerves. In adenomyosis, the trapped blood and glandular tissue cause the surrounding myometrium to hypertrophy, so the uterus becomes globally enlarged, boggy, and tender.

The distinction that matters clinically is where the disease sits. Adenomyosis is confined to the uterus. Endometriosis is defined by lesions outside the uterus, though rare cases of adenomyosis-like tissue in the bowel or bladder exist. In plain terms: one disease thickens the uterine wall from within, the other seeds inflammation across the pelvis.

Quantified comparison: how the two diseases differ by the numbers

The table below reconciles the main clinical differences. Prevalence figures are estimates, because both conditions are underdiagnosed and depend on whether diagnosis is clinical, imaging-based, or surgical.

The junctional zone threshold deserves a note on consistency. Ultrasound signs and MRI signs do not share cutoffs: MRI commonly uses a junctional zone of 12 mm or more, while ultrasound relies on asymmetric thickening and cystic myometrial changes. A clinician may describe the same uterus differently depending on which test was used.

Adenomyosis in depth: a wall thickened by trapped blood

Adenomyosis affects an estimated 20 to 35 percent of women who seek care for pelvic symptoms, and it appears in up to 70 percent of uterus specimens removed for benign reasons. The classic presentation is heavy menstrual bleeding plus a globally enlarged, tender uterus in a woman in her late 30s or 40s. Many women have been pregnant, though nulliparity does not rule it out.

Imaging findings center on the junctional zone, the band of muscle just inside the endometrium. On MRI, a junctional zone of 12 mm or more, or a ratio to myometrial thickness above 40 percent, supports the diagnosis. On ultrasound, the signs are asymmetric wall thickening, small myometrial cysts, and a fan-shaped shadowing pattern.

Two mechanisms explain the bleeding. First, the displaced glands enlarge the cavity surface, so the lining sheds over a larger area. Second, the hypertrophied muscle contracts poorly, so the uterine cavity fails to compress vessels effectively. In plain terms: there is more lining to shed and less muscle squeeze to stop the flow.

Adenomyosis also raises miscarriage risk. Studies place the spontaneous miscarriage rate in affected women at roughly 1.5 to 2 times the background rate, likely through impaired implantation and altered junctional zone contractility. This is an association, not proof of causation, and the evidence base is modest.

Endometriosis in depth: lesions outside the uterus that inflame the pelvis

Endometriosis affects roughly 6 to 10 percent of reproductive-age women, and it is found in 35 to 50 percent of women investigated for infertility. The most common sites are the pelvic peritoneum, the ovarian surface, and the rectovaginal septum. Deep infiltrating endometriosis can involve the bowel, bladder, and ureter, and each site brings its own symptoms.

The cardinal symptom is cyclic pain that worsens over time, often with deep dyspareunia and pain with bowel movements during menses. Ovarian endometriomas, fluid-filled cysts lined by endometrial tissue, can reach several centimeters and distort ovarian anatomy. Nodules of 1 cm or more in the rectovaginal septum correlate with more severe pain and a higher risk of bowel involvement.

Laparoscopy remains the reference standard for diagnosis of peritoneal disease, but it has limits. Small superficial lesions can be missed, and a negative laparoscopy does not exclude the disease. Image-based detection works best for deep infiltrating disease and endometriomas, with sensitivities above 80 percent at expert centers for those specific patterns. That asymmetry means a normal scan proves nothing, while a positive scan is highly informative.

Fertility impact runs through two channels: mechanical distortion of tubes and ovaries, and an inflammatory pelvic environment that impairs sperm function and embryo quality. Surgical excision of endometriomas and deep lesions improves pain and, in selected cases, fertility, though repeat surgery can damage ovarian reserve.

When both diseases coexist: the overlap case

Roughly 20 percent of women with adenomyosis also have endometriosis, and the reverse overlap is similarly common in surgical series. The combination produces more severe symptoms than either condition alone: heavier bleeding from the adenomyosis plus the inflammatory pain of endometriosis.

This overlap explains a common clinical frustration. A woman treated with hormonal therapy may see her bleeding improve while pelvic pain persists, or the reverse. When symptoms do not respond to a single-line treatment, clinicians should consider that two diseases are driving two different symptom clusters. In plain terms: treating one engine leaves the other running.

The overlap also affects surgical planning. Hysterectomy definitively treats adenomyosis but does not remove peritoneal or ovarian endometriosis. Excision surgery addresses endometriosis but leaves the adenomyotic uterus in place. For women with both, the treatment sequence must match which disease is dominant.

Timeline: what happens, and when, in each disease

The time course differs sharply between the two conditions. This table covers typical milestones and diagnostic delays, drawn from cohort and registry data.

The diagnostic delay gap is the most striking number. Endometriosis takes an estimated 7 to 10 years to diagnose, largely because cyclic pain in adolescents is dismissed as normal menstruation. Adenomyosis is diagnosed faster because imaging finds an enlarged uterus incidentally, often during a fertility workup.

Misconceptions and edge cases that change management

Several widespread beliefs are wrong or incomplete, and each one affects treatment choices.

The first is that adenomyosis only affects older women after childbirth. Imaging studies now detect it in women in their 20s and in nulliparous women, and it should be considered in any woman with heavy periods and an enlarged uterus.

The second is that a normal ultrasound excludes disease. Ultrasound misses small peritoneal endometriosis entirely and can underdetect adenomyosis in mild cases. A normal scan lowers probability but does not rule either disease out.

The third is that hysterectomy cures all pelvic pain. Hysterectomy removes adenomyosis and the uterus, but it does not excise endometriosis outside the uterus. Women with both conditions may have persistent pain after hysterectomy if endometriosis was left behind.

The fourth is the fertility myth. Endometriosis does not make pregnancy impossible, and adenomyosis does not prevent conception. Both raise risk, and both are managed with fertility-directed planning rather than avoidance of pregnancy.

An edge case worth flagging: adenomyosis and uterine fibroids frequently coexist, and both enlarge the uterus and cause heavy bleeding. Fibroids are discrete, well-circumscribed masses, while adenomyosis is diffuse and poorly demarcated. Misreading one for the other can lead to the wrong surgery.

Red flags that need urgent evaluation

Most pelvic pain is not an emergency, but certain features require prompt assessment. Seek urgent care for:

• Sudden severe pelvic pain with fainting, which may indicate a ruptured endometrioma or ectopic pregnancy
• Heavy bleeding soaking a pad or tampon every hour for more than 2 hours
• Fever with pelvic pain and abnormal discharge, which can signify pelvic infection
• New bowel or bladder symptoms, including blood in stool or urine during menses
• Pain that no longer responds to over-the-counter NSAIDs at recommended doses
• Infertility lasting 12 months or more, or 6 months if age 35 or older

What to actually do: a practical sequence

Start with a symptom diary covering cycle length, bleeding volume, and pain scores on a 0 to 10 scale. Bring two to three months of records to the first appointment. This single step shortens diagnostic delay more than any test.

Ask for a transvaginal ultrasound as the first imaging test if heavy bleeding or an enlarged uterus is suspected. If adenomyosis is suspected and ultrasound is inconclusive, MRI adds specificity, particularly for junctional zone measurement. If endometriosis is suspected and imaging is normal, ask whether referral to a gynecologist with expertise in laparoscopic diagnosis is appropriate.

For symptom control, NSAIDs taken at the first sign of bleeding reduce prostaglandin-driven pain. Hormonal options, including the levonorgestrel intrauterine device for bleeding control and combined contraceptives for pain, are first-line and can be used together. Tranexamic acid reduces menstrual blood loss by roughly 30 to 55 percent and is a reasonable adjunct for heavy bleeding.

For fertility planning, request referral to a reproductive endocrinologist before surgery if pregnancy is a goal. Surgical decisions should account for both diseases, and the sequence should be set by which condition dominates the symptom picture.

Practical limits and what the evidence cannot yet say

Both diseases are underdiagnosed, and prevalence figures are estimates rather than counts. Imaging criteria are not fully standardized across centers, and no single noninvasive test replaces histology or laparoscopy for definitive diagnosis. The overlap rate of roughly 20 percent is drawn from surgical series and may overestimate coexistence in the general population.

Treatment evidence is strongest for symptom control and weakest for long-term disease modification. No therapy has been shown to prevent adenomyosis or endometriosis from developing. Research directions include nerve-sensitization pathways, immune dysregulation, and nonhormonal targets, but these remain hypotheses rather than established care.

The practical takeaway is that both diseases are legitimate, diagnosable, and treatable. The pathway is symptom documentation, appropriate imaging, referral to a specialist when needed, and a treatment plan that accounts for the possibility that both conditions are present at once.